Anti-Dxd (Exatecan derivative for ADC) antibody, mAb

Background

Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a

conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to human cancer cell lines of KPL-4,

NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM, but the control IgG-ADC (Dxd is the

payload) shows no inhibition on the four cell lines (with HER2 expression).

#YKMP18020 monoclonal antibody can recognize Dxd and Dxd structurally similar molecules.

Immunogen: Dxd-KLH

Specificity: Specifically recognizes the target-DXD

Source: Mouse, Monoclonal Clone #13

Isotype: IgG1

Conjugate: Unconjugated

Concentration: 1.0 mg/ml

Purity: > 90% as determined by SDS-PAGE

Tested applications: ELISA

Recommended dilution: 1:1,000-1:5,000 (optimal dilutions should be determined by the end use.)

Storage Buffer: PBS Buffer, pH7.4

Storage: Store at 2°C to 8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Stable for 2

years from date of receipt. Aliquot to avoid repeated freezing and thawing